Document Detail


Antioxidants as adjuvant therapy in rheumatoid disease. A preliminary study.
MedLine Citation:
PMID:  11367869     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of the present study was to assess the therapeutic value of adding a high dose of vitamin E or an antioxidant combination to the treatment regimen of the rheumatoid disease. The study was carried out on 30 patients with rheumatoid disease diagnosed according to the criteria of American Rheumatism Association (ARA), subvided into three equal groups. Patients in group I received a standard treatment of intramuscular methotrexate (CAS 59-05-2; 12.5 mg/week), oral sulphasalazine (CAS 599-79-1; 0.5 g b.i.d.) and indometacin (CAS 53-86-1; 100 mg suppository at bed-time). In group II the patients received the standard treatment plus a combination of antioxidants. Patients in group III received a high dose of vitamin E (400 mg t.i.d.) in addition to the standard treatment. The disease state was evaluated using Ritchle's articular score index and the duration of morning stiffness. Laboratory evaluations included the rheumatoid factor, erythrocyte sedimentation rate (ESR), plasma levels of vitamin E and malonedialdehyde (MDA), and the activity of glutathione peroxidase (GPx). In the group receiving the standard regimen, the patients started to feel tangible improvement by the end of the second month. With adjuvant therapy of either the antioxidant combination or a high dose of vitamin E the symptoms of arthritis were better controlled from the first month. By the end of the second month, the values of the three monitoring tests were significantly decreased indicating better control of the disease. The percentage increase in the activity of GPx was highest in patients taking the antioxidant combination and least in those taking the standard treatment. The decrease in plasma MDA followed the same pattern. With adjuvant therapy, the vitamin E level in plasma increased with the duration of treatment. The results obtained in the present study are encouraging. The clinical improvement and the shift in the disease indices towards normal make the use of antioxidants as adjuvant therapy in rheumatoid disease worth pursuing.
Authors:
M Helmy; M Shohayeb; M H Helmy; E A el-Bassiouni
Related Documents :
1713269 - Therapeutic use of monoclonal anti-cd4 antibody in rheumatoid arthritis.
24801119 - Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of ...
11665979 - Infliximab in patients with primary sjögren's syndrome: a pilot study.
18651339 - Improvement of subjective well-being and enduring symptomatic remission, a 5-year follo...
23645049 - Primary percutaneous coronary intervention in nonagenarians: six-month outcomes from a ...
15113999 - Benefit of very early referral and very early therapy with disease-modifying anti-rheum...
1444509 - Alopecia areata. a review of therapy, efficacy, safety, and mechanism.
17062049 - A simple and practical method in treatment of ingrown nails: splinting by flexible tube.
3496469 - Experience in vibratory and electro-ejaculation techniques in spinal cord injury patien...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Arzneimittel-Forschung     Volume:  51     ISSN:  0004-4172     ISO Abbreviation:  Arzneimittelforschung     Publication Date:  2001  
Date Detail:
Created Date:  2001-05-22     Completed Date:  2001-06-28     Revised Date:  2006-09-18    
Medline Journal Info:
Nlm Unique ID:  0372660     Medline TA:  Arzneimittelforschung     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  293-8     Citation Subset:  IM    
Affiliation:
Unit of Rheumatology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Antioxidants / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / blood,  drug therapy*
Biological Markers
Drug Therapy, Combination
Female
Humans
Indomethacin / therapeutic use
Male
Methotrexate / therapeutic use
Middle Aged
Sulfasalazine / therapeutic use
Vitamin E / therapeutic use*
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Antioxidants; 0/Antirheumatic Agents; 0/Biological Markers; 1406-18-4/Vitamin E; 53-86-1/Indomethacin; 59-05-2/Methotrexate; 599-79-1/Sulfasalazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Synthesis, evaluation and structure-activity relationships of 5-alkyl-2,3-dihydroimidazo[1,2-c] quin...
Next Document:  In vitro melanin binding of NS-49, a phenethylamine class alpha 1A-adrenoceptor agonist.